Management of hepatitis B reactivation in patients receiving cancer chemotherapy

Yi Wen Huang, Raymond T. Chung

研究成果: 雜誌貢獻文章同行評審

22 引文 斯高帕斯(Scopus)

摘要

Hepatitis B virus (HBV) reactivation is well documented in previously resolved or inactive HBV carriers who receive cancer chemotherapy. The consequences of HBV reactivation range from self-limited conditions to fulminant hepatic failure and death. HBV reactivation also leads to premature termination of chemotherapy or delay in treatment schedules. This review summarizes current knowledge of management of HBV reactivation in patients receiving cancer chemotherapy. HBV surface antigen (HBsAg) testing should be performed in patients who require cancer chemotherapy. Four meta-analyses support lamivudine prophylaxis for HBV reactivation during chemotherapy in HBsAg-positive patients. Randomized controlled trials to compare different HBV antiviral agents are needed to define optimal regimens for the prevention and treatment of HBV reactivation in patients receiving cancer chemotherapy.

原文英語
頁(從 - 到)359-370
頁數12
期刊Therapeutic Advances in Gastroenterology
5
發行號5
DOIs
出版狀態已發佈 - 九月 2012
對外發佈

ASJC Scopus subject areas

  • 消化內科

指紋

深入研究「Management of hepatitis B reactivation in patients receiving cancer chemotherapy」主題。共同形成了獨特的指紋。

引用此